腸から十分に栄養を吸収できない子どもの「腸管不全」で合併症の「肝障害（IFALD）」を回避しながら栄養補給できるとされる国内未承認薬について、東北大は24日までに、医師主導治験の投与が終了したと発表 ...

腸から十分に栄養を吸収できない子どもの「腸管不全」で合併症の「肝障害（IFALD）」を回避しながら栄養補給できるとされる国内未承認薬について、東北大は医師主導治験の投与が終了したと発表した。得られたデータを解析して製造元企業と連携し、2027年以降の薬事承認申請を目指す。和田基教授は「国内承認、保険適用に向けた極めて大きな一歩だ。重篤な病気と闘う子どもたちの命を守ることにつながる」と話した。

Svar fra ministeren for natur og dyrevelfærd til Anna Bjerre MOF spørgsmål 353 (alm. del)

Short bowel syndrome (SBS), usually resulting from massive small bowel resections or congenital defects, may lead to intestinal failure (IF), requiring intravenous fluids and parenteral nutrition to preserve patients’ nutritional status. Approximately 15% to 40% of subjects with SBS and IF develop chronic hepatic damage during their life, a condition referred to as intestinal-failure-associated liver disease (IFALD), which ranges from steatosis to fibrosis or end-stage liver disease. Parenteral nutrition has been largely pointed out as the main pathogenetic factor for IFALD. However, other elements, such as inflammation, bile acid metabolism, bacterial overgrowth and gut dysbiosis also contribute to the development of liver damage and may deserve specific treatment strategies. Indeed, in our review, we aim to explore IFALD pathogenesis beyond parenteral nutrition. By critically analyzing recent literature, we seek to delve with molecular mechanisms and metabolic pathways underlying liver damage in such a complex set of patients.